Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34433903

about

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation.

P2860

Q28079320-C0E4AFA8-5566-4373-9289-532E1C2E6F22 Q35256622-5EE53ED0-B02B-4BF6-9A7E-B3D372D341D9 Q35782291-7B0ED05E-2054-4F98-BBE8-D377A8417279 Q37637658-4400769E-0E56-4661-9637-5555BF353567 Q38540557-40210C77-6E32-45F0-AF19-8FD85E4FE4D6 Q39129178-232A9943-7452-4DC7-9B46-7B8DEF6811E9 Q46360744-598CF110-EA47-4CA3-9ECB-8D2C3A86624B

P2860

Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34433903

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@ast

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@en

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@nl

type

label

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@ast

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@en

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@nl

prefLabel

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@ast

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@en

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@nl

P1433

Q34433903-0048B87E-6E98-4B03-8F4A-E1A1404C2FD6

P1476

Q34433903-781CCBAE-DD71-4267-A08E-C2735C92EE5B

P2093

Q34433903-3FE1D672-552A-4347-BD1E-9D13CE2528BC

Q34433903-6B6993F3-2CF2-4D41-8206-030B019F17B6

P2860

Q34433903-0035DA1C-5246-4027-977B-93CF57380F2C

Q34433903-00B521D0-E5C4-4572-B375-9F8317047E57

Q34433903-048C933E-5F69-41D8-B6A4-D56BE1329813

Q34433903-0532B910-4AF0-4BF9-9F25-E7268E99B9AF

Q34433903-0B336B72-5FEB-4650-9AAB-7FBE5F62832D

Q34433903-0CF1168E-F57C-49FA-B715-7AA1ACA1C0F9

Q34433903-1460B506-47F8-410F-8BAA-949668B470F9

Q34433903-1599F9B8-E010-4EEF-A282-09D79DBA4FA2

Q34433903-1646EFE0-8AD9-48D9-A11D-DD4838BF2BDF

Q34433903-170F328F-3B5B-43B1-B897-56E5266656B1

P2888

Q34433903-2D2A69CD-D51D-44FB-BCE3-3A49969FC567

P304

Q34433903-043062E1-1EE7-4131-B7CA-73A5C239260B

P31

Q34433903-0041a212-11db-469b-9164-99d90548ed9c

Q34433903-2C14065F-4E94-459E-967F-D4FF03C87AA7

P356

Q34433903-32D1828A-CB86-4605-BE97-E3726E8FCA58

P478

Q34433903-D2AFB3DF-418F-4459-9FE6-16EB66F3150B

P577

Q34433903-F964B82D-DEEB-4D00-A4DA-7BAC4F29BD89

P5875

Q34433903-8F42E214-2BBE-4C63-A148-00D06001DA95

P6179

Q34433903-B25509AC-16EE-42FE-A2FE-9A083A9D5BFA

P698

Q34433903-ED675FF3-141D-4ABE-9C75-997D095461BC

P932

Q34433903-24307BE1-F38D-4CAE-AA45-11DC86E32EC6

P356

P1433

Translational respiratory medicine

P1476

Second generation tyrosine kin ...... ic non-small-cell lung cancer.

@en

P2093

Federico Cappuzzo

http://www.w3.org/2001/XMLSchema#string

Irene Stasi

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

P2888

P304

2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2213-0802-2-2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269720871

http://www.w3.org/2001/XMLSchema#string

P6179

1012705731

http://www.w3.org/2001/XMLSchema#string

P698

25505694

http://www.w3.org/2001/XMLSchema#string

P932

4215821

http://www.w3.org/2001/XMLSchema#string